Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
22 hedge funds and large institutions have $8.79M invested in Amplify Treatments, Testing and Advancements ETF in 2021 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 5 closing their positions.
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
68% more capital invested
Capital invested by funds: $5.23M → $8.79M (+$3.57M)
12% less funds holding
Funds holding: 25 → 22 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$1.89M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$515K |
| 3 |
LPL Financial
San Diego,
California
|
+$447K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$251K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$130K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$245K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$78.9K |
| 3 |
CMA
Cedar Mountain Advisors
Lake Oswego,
Oregon
|
-$35K |
| 4 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$31K |
| 5 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
-$31K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GWM
26
Geneos Wealth Management
Englewood,
Colorado
| – | -$17K | -500 | Closed |
|
27
Bank of America
Charlotte,
North Carolina
| – | -$6K | -200 | Closed |
|
GERM Hedge Fund Activity: Q1 2021 in Review
22 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q1 2021, worth a combined $8.79M — up 68% from $5.23M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of GERM and 2 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 10 added.
The largest buyer was Jane Street, opening a new position worth an estimated $1.89M. The largest seller was Osaic Holdings, cutting an estimated $245K.
- 22 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q1 2021, down from 25 in Q4 2020.
- Funds reported $8.79M of Amplify Treatments, Testing and Advancements ETF stock for Q1 2021, up 68% quarter-over-quarter.
- 2 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q1 2021 and 5 closed out, a net change of -3 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q1 2021 was Jane Street, an estimated $1.89M added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q1 2021 was Osaic Holdings, an estimated $245K sold.
Based on aggregated 13F filings for Q1 2021.